• Je něco špatně v tomto záznamu ?

IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma

N. Prokoph, NA. Probst, LC. Lee, JM. Monahan, JD. Matthews, HC. Liang, K. Bahnsen, IA. Montes-Mojarro, E. Karaca-Atabay, GG. Sharma, V. Malik, H. Larose, SD. Forde, SP. Ducray, C. Lobello, Q. Wang, SL. Luan, Š. Pospíšilová, C....

. 2020 ; 136 (14) : 1657-1669. [pub] 20201001

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012058

Grantová podpora
R01 CA196703 NCI NIH HHS - United States
RG86786 Cancer Research UK - United Kingdom

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.

Center for Biomarker Research in Medicine Vienna Core Lab2 Medical University of Vienna Vienna Austria

Central European Institute of Technology Masaryk University Brno Czech Republic

Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna Vienna Austria

Department of Clinical Research Gustave Roussy Cancer Center Villejuif France

Department of Experimental Pathology and Laboratory Animal Pathology Institute of Clinical Pathology Medical University of Vienna Vienna Austria

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Medicine Columbia Center for Human Development Columbia University Irving Medical Center New York NY

Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy

Department of Pathology and Laboratory Medicine Aga Khan University Hospital Karachi Pakistan

Department of Pathology Boston Children's Hospital and Harvard Medical School Boston MA

Department of Pathology CHU Necker Enfants Malades Paris France

Department of Pathology Hematopathology Section Universitätsklinikum Schleswig Holstein Campus Kiel Kiel Germany

Department of Pediatric Adolescent and Young Adult Oncology Institute Curie Medical Centre Paris France

Department of Pediatric and Adolescent Oncology Gustave Roussy Cancer Center Villejuif France

Department of Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Vienna Austria

Department of Pediatric Hematology and Oncology University Hospital Hamburg Eppendorf Hamburg Germany

Department of Pediatric Hematology Oncology and Palliative Care Addenbrooke's Hospital Cambridge University Hospitals National Health Service Foundation Trust Cambridge United Kingdom

Department of Pediatric Oncology and Hematology Sorbonne Université Trousseau Hospital Assistance Publique Hôpitaux de Paris Paris France

Department of Pediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Cambridge United Kingdom

Equipe Integrated Cancer Research Site Institut Curie Paris France

European Molecular Biology Laboratory European Bioinformatics Institute Hinxton Cambridge United Kingdom

Experimental and Laboratory Animal Pathology Department of Pathology Medical University of Vienna Vienna Austria

INSERM U1015 Université Paris Saclay Villejuif France

INSERM U830 Transfer Department Laboratoire de Génétique et Biologie des Cancers Institut Curie Paris France

Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen University Hospital Tübingen Eberhard Karls University Tübingen Germany

Oncology Center SIREDO Institut Curie Paris France

School of Biomedical Sciences Li Ka Shing Faculty of Medicine The University of Hong Kong Pokfulam Hong Kong China

School of Medicine and Surgery University of Milano Bicocca Monza Italy

Unit of Laboratory Animal Pathology University of Veterinary Medicine Vienna Vienna Austria

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012058
003      
CZ-PrNML
005      
20210507101739.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2019003793 $2 doi
035    __
$a (PubMed)32573700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Prokoph, Nina $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
245    10
$a IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma / $c N. Prokoph, NA. Probst, LC. Lee, JM. Monahan, JD. Matthews, HC. Liang, K. Bahnsen, IA. Montes-Mojarro, E. Karaca-Atabay, GG. Sharma, V. Malik, H. Larose, SD. Forde, SP. Ducray, C. Lobello, Q. Wang, SL. Luan, Š. Pospíšilová, C. Gambacorti-Passerini, GAA. Burke, S. Pervez, A. Attarbaschi, A. Janíková, H. Pacquement, J. Landman-Parker, A. Lambilliotte, G. Schleiermacher, W. Klapper, R. Jauch, W. Woessmann, G. Vassal, L. Kenner, O. Merkel, L. Mologni, R. Chiarle, L. Brugières, B. Geoerger, I. Barbieri, SD. Turner
520    9_
$a Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.
650    _2
$a antitumorózní látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a CRISPR-Cas systémy $7 D064113
650    _2
$a buněčné linie $7 D002460
650    _2
$a krizotinib $x farmakologie $x terapeutické užití $7 D000077547
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a editace genu $7 D000072669
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a receptor interleukinu-10 - alfa-podjednotka $x genetika $x metabolismus $7 D053709
650    _2
$a anaplastický velkobuněčný lymfom $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D017728
650    _2
$a biologické modely $7 D008954
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a tyrosinkinasy $x genetika $x metabolismus $7 D011505
650    _2
$a transkripční faktor STAT3 $x metabolismus $7 D050796
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Probst, Nicola A $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Lee, Liam C $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Monahan, Jack M $u European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, United Kingdom
700    1_
$a Matthews, Jamie D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Liang, Huan-Chang $u Experimental and Laboratory Animal Pathology, Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Bahnsen, Klaas $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Montes-Mojarro, Ivonne A $u Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany
700    1_
$a Karaca-Atabay, Elif $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
700    1_
$a Sharma, Geeta G $u School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Malik, Vikas $u Department of Medicine, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY
700    1_
$a Larose, Hugo $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Forde, Sorcha D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Ducray, Stephen P $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Lobello, Cosimo $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Wang, Qi $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA
700    1_
$a Luan, Shi-Lu $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Pospíšilová, Šárka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Gambacorti-Passerini, Carlo $u School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Burke, G A Amos $u Department of Pediatric Hematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, United Kingdom
700    1_
$a Pervez, Shahid $u Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan
700    1_
$a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Janíková, Andrea $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Pacquement, Hélène $u Department of Pediatric, Adolescent, and Young Adult Oncology, Institute Curie Medical Centre, Paris, France
700    1_
$a Landman-Parker, Judith $u Department of Pediatric Oncology and Hematology, Sorbonne Université/Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
700    1_
$a Lambilliotte, Anne $u Department of Pathology, (AP-HP), CHU Necker-Enfants Malades, Paris, France
700    1_
$a Schleiermacher, Gudrun $u Oncology Center SIREDO (Care, Innovation, Research for Cancer in Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France $u INSERM U830 Transfer Department, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France $u Equipe Integrated Cancer Research Site (SiRIC) Recherche Translationelle en Oncologie Pédiatrique (RTOP), Institut Curie, Paris, France
700    1_
$a Klapper, Wolfram $u Department of Pathology, Hematopathology Section, Universitätsklinikum Schleswig-Holstein (UKSH) Campus Kiel, Kiel, Germany
700    1_
$a Jauch, Ralf $u School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
700    1_
$a Woessmann, Wilhelm $u Department of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Vassal, Gilles $u Department of Clinical Research, Gustave Roussy Cancer Center, Villejuif, France
700    1_
$a Kenner, Lukas $u Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria $u Center for Biomarker Research in Medicine (CBmed) Vienna, Core-Lab2, Medical University of Vienna, Vienna, Austria
700    1_
$a Merkel, Olaf $u Experimental and Laboratory Animal Pathology, Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Mologni, Luca $u School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Chiarle, Roberto $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
700    1_
$a Brugières, Laurence $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France; and
700    1_
$a Geoerger, Birgit $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France; and $u INSERM U1015, Université Paris-Saclay, Villejuif, France
700    1_
$a Barbieri, Isaia $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 136, č. 14 (2020), s. 1657-1669
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32573700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101739 $b ABA008
999    __
$a ok $b bmc $g 1650439 $s 1132437
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 136 $c 14 $d 1657-1669 $e 20201001 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a R01 CA196703 $p NCI NIH HHS $2 United States
GRA    __
$a RG86786 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20210420
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace